Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant

Discovery of survival predictor and early monitoring biomarkers for EGFR tyrosine kinase inhibitor therapy in lung adenocarcinoma by integrative omics analysis

The FASEB Journal ◽

10.1096/fasebj.2020.34.s1.08868 ◽

2020 ◽

Vol 34 (S1) ◽

pp. 1-1

Author(s):

Ting-Feng Hsiao ◽

Chih-Liang Wang ◽

Yi-Cheng Wu ◽

Hsiang-Pu Feng ◽

Yen-Chuan Chiu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Survival Predictor ◽

Integrative Omics

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Scientific Reports ◽

10.1038/srep33505 ◽

2016 ◽

Vol 6 (1) ◽

Cited By ~ 27

Author(s):

Anja Lisa Riediger ◽

Steffen Dietz ◽

Uwe Schirmer ◽

Michael Meister ◽

Ingrid Heinzmann-Groth ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Mutation Analysis ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Plasma Dna ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival

Pathology - Research and Practice ◽

10.1016/j.prp.2018.01.010 ◽

2018 ◽

Vol 214 (3) ◽

pp. 335-342 ◽

Cited By ~ 4

Author(s):

Soon Auck Hong ◽

Si-Hyong Jang ◽

Mee-Hye Oh ◽

Sung Joon Kim ◽

Jin-Hyung Kang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Poor Survival ◽

Egfr Mutant

EGFR Tyrosine Kinase Inhibitor Therapy

10.32388/sxaqtc ◽

2020 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-3972 ◽

2020 ◽

pp. clincanres.3972.2019

Author(s):

Ting-Feng Hsiao ◽

Chih-Liang Wang ◽

Yi-Cheng Wu ◽

Hsiang-Pu Feng ◽

Yen-Chuan Chiu ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Survival Predictor ◽

Integrative Omics

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Line Treatment ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Oncology Letters ◽

10.3892/ol.2019.10942 ◽

2019 ◽

Author(s):

Ching‑Hu Chung

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Tyrosine Kinase ◽

Clinical Outcomes ◽

Kinase Inhibitor ◽

Cancer Treatments ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

BMC Cancer ◽

10.1186/s12885-018-5116-9 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Eun Young Kim ◽

Arum Kim ◽

Gaeun Lee ◽

Hangsuck Lee ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase